Arcutis Biotherapeutics, Inc.
ARQT
$14.61
-$0.11-0.75%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 83.72% | 7.21% | 26.28% | 55.83% | 7.96% |
| Total Depreciation and Amortization | 18.96% | 270.03% | -9.07% | -1.38% | 10.95% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 20.61% | -3.69% | 13.03% | 5.52% | 15.26% |
| Change in Net Operating Assets | -481.27% | 58.56% | 25.48% | 39.57% | 105.54% |
| Cash from Operations | 98.67% | 21.13% | 32.14% | 60.67% | 20.86% |
| Capital Expenditure | 100.00% | -123.44% | -- | -- | 95.12% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 156.09% | 86.17% | -169.51% | -126.61% | -246.91% |
| Cash from Investing | 156.08% | 86.12% | -169.72% | -126.63% | -247.36% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -97.39% | -54.56% | 36.36% | 161,664.00% | 10,221.10% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -198.11% | -54.56% | 36.36% | 161,664.00% | 10,221.10% |
| Foreign Exchange rate Adjustments | -444.12% | 230.67% | -388.89% | -40.38% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -233.02% | 2,045.99% | -546.36% | 269.30% | 31.64% |